Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | FAAH | O00519 | 6/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9483448 | 0.88 | RAB9A (0.76) | RAB9ASMN1; SMN2NPC1ALDH1A1TP53 | |
| SCHEMBL27989738 | 0.85 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3765824 | 0.84 | RAB9A (0.69) | RAB9ASMN1; SMN2NPC1ALDH1A1TP53 | |
| SCHEMBL10118238 | 0.83 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1ALDH1A1LTA4H | |
| SCHEMBL7564852 | 0.83 | RAB9A (0.79) | RAB9ASMN1; SMN2NPC1ALDH1A1FAAH | |
| SCHEMBL1224023 | 0.82 | TP53 (0.71) | RAB9ASMN1; SMN2NPC1ALDH1A1FAAH | |
| SCHEMBL9565608 | 0.82 | FAAH (0.67) | FAAHTP53 | |
| SCHEMBL16696426 | 0.81 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1ALDH1A1TP53 | |
| SCHEMBL27507535 | 0.81 | RAB9A (0.63) | RAB9ASMN1; SMN2NPC1ALDH1A1FAAH | |
| SCHEMBL8600999 | 0.80 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1ALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003693-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1558591-A4 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | UNIV CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1558591-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | The Regents of the University of California (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| WO-2004033422-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048337-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | RAB9A 870/4885SMN1; SMN2 4013/4885NPC1 625/4885 |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | FAAH, FAAH2, CNR2 | RAB9A 944/4885SMN1; SMN2 4010/4885NPC1 727/4885 |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | RAB9A 785/4885SMN1; SMN2 3832/4885NPC1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.